Introduction
Colorectal cancer is one of the most common types of cancer and the second greatest cause of cancer-associated mortality in the United States (1) . Epidemiological investigation has revealed the highest incidence of colorectal cancer in North America and Australia, suggesting it is a disease associated with lifestyle (1) . With changing diet in China, the incidence and mortality of colorectal cancer are increasing markedly. Although surgical resection, radiotherapy, chemotherapy and targeted therapies are available for the treatment of colorectal cancer, recurrence and metastasis (20-40% of patients present with liver metastases at diagnosis) remain a cause of poor prognosis.
It has been proposed that a small group of cells exists in tumors with properties of stem cells, including self-renewal, multilineage differentiation, multidrug resistance and tumorigenesis. These cells are considered cancer stem cells and the source of the recurrence and metastasis of colorectal cancer (2, 3) . Previous studies have revealed that epithelial cell adhesion molecule-high (EpCAM high )/cluster of differentiation (CD)44 + colorectal cancer cells have such stem cell-like properties, leading to tumorigenesis, invasion and metastasis of colorectal cancer (4) (5) (6) (Fig. 1) . The results were assessed according to Lin et al (9) . Briefly, CD44 staining was detected mainly in the membrane and EpCAM staining was detected mainly in the cytoplasm. Fig. 2A) . However, in samples of colorectal cancer and their corresponding liver metastases, EpCAM high /CD44 + cells were visible ( Fig. 2B and 2C ). Double-positive cells accounted for 0.8-3.1% of cells in colorectal tumors. The expression of EpCAM/CD44 was significantly correlated with degree of differentiation, tumor stage, depth of invasion (Dukes' stage) and metastatic status (P<0.05), while there was no correlation with gender, age or the magnitude of the tumor (P>0.05) ( Table I) .
Discussion
Cancer stem cells have the capacity for infinite proliferation and self-renewal, and account for 0.3-2.2% of colorectal cancer cells. They are considered the cause of recurrence, metastasis and drug resistance in tumors (8) . Therefore the identification of cancer stem cells and treatments targeting these cells facilitates elimination of the tumor.
EpCAM, a 40 kDa glycoprotein, functions as an epithelial cell adhesion molecule (11); its expression has been reported as localized to the epithelium along the basolateral surface of the majority of gastrointestinal tract mucosa. EpCAM can inhibit differentiation and promote proliferation (12) . It is expressed in 85% of colorectal carcinomas and is one of the earliest tumor markers to appear that is involved in signal transduction, regeneration of tissue and other biological functions. EpCAM can upregulate the expression of the oncogene c-myc, induce acceleration of the cell cycle and promote proliferation (12) . The overexpression of EpCAM enhances the proliferative and invasive capacities of tumors, while downregulation by RNA interference inhibits these functions (13) .
CD44 is a multifunctional class I transmembrane glycoprotein located on the cytomembrane (14, 15) . As a cell adhesion molecule, CD44 is mainly involved in cell-cell and cell-matrix interactions (16) . CD44 plays a vital role in the regulation of cell adhesion, growth, differentiation, migration and angiogenesis, and contributes to tumor progression by promoting invasion and metastasis (14, 15) . Knockdown of CD44 in primary colon cancer cell lines reduces clonogenicity in vitro and tumorigenicity in vivo (17) . Schulenburg et al isolated CD44
+ and CD44 -cells from colon cancer samples. The authors found that CD44
+ cells had characteristics of stem cells and showed much higher capacity for proliferation and (18) . Thus, CD44 is considered a marker of cancer stem cells. In combination with other surface markers, CD44 can also be used to discriminate between a variety of cancer subsets (19) .
Previous studies have revealed that the composite structure of EpCAM and CD44 can promote invasion and metastasis of tumors more strongly than any single adhesion molecule (20) (21) (22) EpCAM have been developed, which can significantly reduce the size of tumor used alone or in combination with standard treatment, demonstrating the potential of such targeting strategies (26, 27) . Further study and the development of targeted drugs is required to elucidate the mechanisms of colorectal cancer stem cells and improve the clinical prognosis of colorectal cancer. EpCAM high /CD44 + , which is regarded as a marker of colorectal cancer stem cells, is significantly correlated with the invasion and metastasis of colorectal cancer, suggesting that this molecular marker may promote the progression of tumors.
